{
    "data": [
        {
            "id": "69046961ecb8a7000145e247",
            "title": "Trump Tells Republicans To Play &#39;Trump Card&#39; To Immediately End &#39;Country Destroying&#39; Shutdown: &#39;Get Rid Of The...&#39;",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">President <strong>Donald Trump</strong> has called on Senate Republicans to scrap the <a href=\"https://www.benzinga.com/government/21/09/23039200/brookings-institute-heres-how-to-reform-the-filibuster-bring-majority-rule\" target=\"_blank\">filibuster rule</a> requiring 60 votes to move most legislation forward, so they can reopen the government without Democratic backing.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Trump Signals Urgency To Reopen Government</h2><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">In a <strong>Truth Social</strong> post on Thursday, Trump said, “It is now time for the Republicans to play their ‘TRUMP CARD,’ and go for what is called the Nuclear Option — Get rid of the Filibuster, and get rid of it, NOW!” </p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">He also criticized the Democrats’ <a href=\"https://www.benzinga.com/news/politics/25/09/47660523/bernie-sanders-says-trumps-cuts-to-obamacare-must-be-axed-or-else-premiums-will-rise-by-75-no-one-can-afford-that\" target=\"_blank\">healthcare demands</a>, which are at the heart of the current deadlock.</p><!--/$--><!--$--><p class=\"block core-block\">Trump commended the work of Majority Leader <strong>John Thune</strong>, and Speaker of the House <strong>Mike Johnson</strong>. However, he argued that Republicans should act now to end the filibuster, claiming that <a href=\"https://www.benzinga.com/news/24/03/37501170/kyrsten-sinema-who-opposed-democrats-filibuster-rule-announces-retirement-mitch-mcconnell-says-histo\" target=\"_blank\">Democrats would do</a> the same if they regained control of the Senate.</p><!--/$--><!--$--><p class=\"block core-block\">He added, “If we did what we should be doing, it would IMMEDIATELY end this ridiculous, Country destroying ‘SHUT DOWN.'”</p><!--/$--><!--$--><!--/$--><!--$--><div class=\"sc-fzzUx jSgJNL\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">GOP Debates Filibuster Usage</h2><!--/$--><!--$--><p class=\"block core-block\">Senate Republicans have been considering this <a href=\"https://www.benzinga.com/news/politics/25/10/48426011/republicans-are-weighing-an-extreme-option-to-end-government-shutdown-risking-permanent-change-to-senate-rules-and-bipartisan-balance\" target=\"_blank\">“nuclear option</a>” to end the shutdown, a move that would bring about a permanent change to Senate rules and bipartisan balance. Sen. <strong>Rick Scott</strong> (R-Fla.) previously <a href=\"about:blank\" target=\"_blank\">told </a>The Hill, “If we can’t get anything done, that’s what [Democrats] are gonna force.”</p><!--/$--><!--$--><p class=\"block core-block\">Meanwhile, Senate Majority Leader <strong>John Thune</strong> <a href=\"https://www.politico.com/live-updates/2025/10/29/congress/angry-john-thune-democrats-00628293\" target=\"_blank\">told </a>Politico on Wednesday that he plans to “pretty soon” engage with high-ranking Senate Democrats to end the shutdown. Notably, in March, Thune had called out the Democrats’ hypocrisy for using the filibusters ‘left and right.’</p><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Shutdown Weighs On Consumer Spending</h2><!--/$--><!--$--><p class=\"block core-block\">The <a href=\"https://www.benzinga.com/markets/economic-data/25/10/48463099/shutdown-economic-impact-washington-dc-area-consumer-spending-eagle-bancorp-loans\" target=\"_blank\">economic impact </a>of the shutdown is also being felt, with Washington D.C.’s consumer spending falling at rates unseen since the 2008 financial crisis. According to Bank of America Institute data, year-over-year credit and debit card spending dropped 1.4% in the week ending Oct. 18, the sharpest decline since the subprime crisis.</p><!--/$--><!--$--><p class=\"block core-block\">The ongoing shutdown has also <a href=\"https://www.benzinga.com/news/legal/25/10/48485809/trump-administration-sued-over-suspending-food-benefits-amid-shutdown\" target=\"_blank\">led to a lawsuit</a> against the Trump administration, with a coalition of over two dozen states demanding the continuation of the Supplemental Nutrition Assistance Program (SNAP) funding.</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48551650\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><p class=\"block core-block\"><strong>READ NEXT:</strong></p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/news/politics/25/10/48484691/marjorie-taylor-greene-blasts-speaker-mike-johnson-for-keeping-gop-health-care-plans-secret-says-she-has-to-go-to-a-secure-room-to-find-out\" target=\"_blank\">Marjorie Taylor Greene Blasts Speaker Mike Johnson For Keeping GOP Health Care Plans Secret: Says She Has To Go to A Secure Room To ‘Find Out’</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Image via Shutterstock</em></p><!--/$--><!--$--><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/On-Jan-31--2025--In-The-Oval-Office-Of-T.jpeg",
            "link": "https://www.benzinga.com/news/politics/25/10/48551650/trump-tells-republicans-to-play-trump-card-to-immediately-end-country-destroying-shutdown-get-rid-of-the",
            "pub_date": "2025-10-31 15:46:44",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69046a3becb8a7000145e25c",
            "title": "Colgate-Palmolive Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Colgate-Palmolive Company </strong>(NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CL\" target=\"_blank\">CL</a>) will release earnings results for the third quarter, before the <a href=\"https://www.benzinga.com/quote/cl/earnings\" target=\"_blank\">opening bell on Friday, Oct. 31.</a></p><!--/$--><!--$--><p class=\"block core-block\">Analysts expect the New York-based company to report quarterly earnings at 89 cents per share, down from 91 cents per share in the year-ago period. The consensus estimate for Colgate-Palmolive's quarterly revenue is $5.13 billion, compared to $5.03 billion a year earlier, according to data from <a href=\"https://pro.benzinga.com/dashboard\" target=\"_blank\">Benzinga Pro</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">On Aug. 1, Colgate-Palmolive reported second-quarter adjusted earnings per share of 92 cents, beating the analyst consensus estimate of 89 cents.</p><!--/$--><!--$--><p class=\"block core-block\">Colgate-Palmolive shares gained 1% to close at $76.51 on Thursday.</p><!--/$--><!--$--><p class=\"block core-block\">Benzinga readers can access the latest analyst ratings on the <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie\" target=\"_blank\">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p><!--/$--><!--$--><p class=\"block core-block\">Let's have a look at how Benzinga's most-accurate <a href=\"https://www.benzinga.com/quote/cl/analyst-ratings\" target=\"_blank\">analysts have rated the company</a> in the recent period.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>Raymond James analyst Olivia Tong maintained an Outperform rating and cut the price target from $105 to $95 on Oct. 20, 2025. This analyst has an accuracy rate of 65%.</li>\n<li>JP Morgan analyst Andrea Teixeira maintained an Overweight rating and slashed the price target from $95 to $88 on Oct. 10, 2025. This analyst has an accuracy rate of 60%.</li>\n<li>Piper Sandler analyst Michael Lavery assumed a Neutral rating and a price target of $84 on Oct. 3, 2025. This analyst has an accuracy rate of 66%.</li>\n<li>Barclays analyst Lauren Lieberman maintained an Equal-Weight rating and cut the price target from $87 to $82 on Oct. 1, 2025. This analyst has an accuracy rate of 60%.</li>\n<li>Morgan Stanley analyst Dara Mohsenian maintained an Overweight rating and slashed the price target from $104 to $96 on Aug. 4, 2025. This analyst has an accuracy rate of 70%.</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\">Considering buying CL stock? Here’s what analysts think: </p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\"><strong>Read This Next: </strong></p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48524289/jim-cramer-likes-toast-but-isnt-buying-shares-yet\" target=\"_blank\">Jim Cramer Likes Toast, But Isn’t Buying Shares—Yet</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\">Photo via Shutterstock</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48551672\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/Milan--Italy---August-10--2017-Colgate-p.jpeg",
            "link": "https://www.benzinga.com/analyst-stock-ratings/price-target/25/10/48551672/colgate-palmolive-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-3",
            "pub_date": "2025-10-31 15:50:23",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "690466bcecb8a7000145e169",
            "title": "Tesla Prototype Spotted — Could This Be Cybercab With Steering Wheel?",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\">Days after <strong>Robyn Denholm</strong>, Chair of the <strong>Tesla Inc.</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/TSLA\" target=\"_blank\">TSLA</a>) Board of Directors, hinted at the possibility of a Cybercab with a <a href=\"https://www.benzinga.com/markets/tech/25/10/48484642/teslas-cybercab-may-get-steering-wheel-pedals-coming-around-to-reality-says-ross-gerber\" target=\"_blank\">steering wheel and pedals</a>, pictures of the autonomous vehicle with a supposed steering wheel have surfaced on social media.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Check out the current price of TSLA</em><a href=\"https://benzinga.com/quote/TSLA\" target=\"_blank\"><em> </em><em>here</em></a><em>.</em></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Cybercab Spotted With A Steering Wheel</h2><!--/$--><!--$--><p class=\"block core-block\">In a post shared by <strong>Sawyer Merritt</strong> on the social media platform X on Thursday, the influencer showcased a photo of a Tesla Cybercab undergoing testing on public roads. \"Oh hello Cybercab,\" the influencer said in the post.</p><!--/$--><!--$--><p class=\"block core-block\">What's interesting is that the picture showcases the passenger’s hand positioning in the Cybercab, seemingly holding on to what could be a steering wheel.</p><!--/$--><!--$--><!--/$--><!--$--><h2 class=\"wp-block-heading\">Cybercab Production, Ross Gerber's Suggestion</h2><!--/$--><!--$--><p class=\"block core-block\">The news comes as Denholm, in a recent interview, also shared that the Cybercab, with the steering wheel and pedals, could also be the rumored Tesla Model 2.</p><!--/$--><!--$--><div class=\"sc-SfCGz ciVbir\"></div><!--/$--><!--$--><p class=\"block core-block\">Tesla also recently shared <a href=\"https://www.benzinga.com/markets/tech/25/10/48518730/tesla-gears-up-for-cybercab-production-at-gigafactory-texas-posts-multiple-job-listings\" target=\"_blank\">multiple job listings</a> on its official website, detailing open positions for the Cybercab's production at the company's Gigafactory in Texas.</p><!--/$--><!--$--><p class=\"block core-block\">Meanwhile, investor <strong>Ross Gerber</strong>, co-founder of investment firm <strong>Gerber Kawasaki</strong>, had earlier suggested <a href=\"https://www.benzinga.com/markets/tech/25/10/48116757/ross-gerber-has-this-cybercab-suggestion-for-elon-musk-amid-affordable-model-y-buzz-put-a-steering\" target=\"_blank\">Tesla could offer the Cybercab</a> with a steering wheel and pedals and sell it as an affordable model in the lineup. He added that the company could find a market for the product.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Tesla Cybercab APAC Debut</h2><!--/$--><!--$--><p class=\"block core-block\">The Cybercab is also reportedly <a href=\"https://www.benzinga.com/markets/tech/25/10/48520789/tesla-cybercab-to-make-apac-debut-at-chinas-annual-import-expo-in-shanghai-optimus-could-also-be-showcased\" target=\"_blank\">set for its APAC debut</a> as Tesla will showcase the autonomous vehicle at the China Import Expo next month in Shanghai. The company could also showcase the Optimus humanoid robot at the event.</p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\">Tesla scores well on Momentum and Quality metrics, while offering satisfactory Growth, but poor Value. Tesla also has a favorable price trend in the Short, Medium and Long term. For more such insights, sign up for<a href=\"https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound\" target=\"_blank\"> Benzinga Edge Stock Rankings</a> today!</p><!--/$--><!--$--><p class=\"block core-block\"><em>Check out more of Benzinga's Future Of Mobility coverage by</em><a href=\"https://www.benzinga.com/topic/mobility\" target=\"_blank\"><em> following this link.</em></a></p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48551427\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><a href=\"https://www.benzinga.com/markets/tech/25/10/48549741/openais-sam-altman-calls-out-tesla-after-failing-to-get-50k-roadster-refund-felt-like-a-long-time\" target=\"_blank\"><strong>OpenAI's Sam Altman Calls Out Tesla After Failing To Get $50K Roadster Refund: ‘Felt Like A Long Time…'</strong></a></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo courtesy: Shutterstock</em></p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/Fremont--Ca--Usa---Feb-21--2024-Tesla-Su.jpeg",
            "link": "https://www.benzinga.com/markets/tech/25/10/48551427/tesla-prototype-spotted-could-this-be-cybercab-with-steering-wheel",
            "pub_date": "2025-10-31 15:35:27",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69046567ecb8a7000145e156",
            "title": "Top Wall Street Forecasters Revamp Chevron Expectations Ahead Of Q3 Earnings",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>Chevron Corporation</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/CVX\" target=\"_blank\">CVX</a>) will release earnings results for the third quarter, before the <a href=\"https://www.benzinga.com/quote/CVX/earnings\" target=\"_blank\">opening bell on Friday, Oct. 31.</a></p><!--/$--><!--$--><p class=\"block core-block\">Analysts expect the Houston, Texas-based company to report quarterly earnings at $1.71 per share, down from $2.51 per share in the year-ago period. The consensus estimate for Chevron's quarterly revenue is $49.01 billion, compared to $50.67 billion a year earlier, according to data from <a href=\"https://pro.benzinga.com/dashboard\" target=\"_blank\">Benzinga Pro</a>.</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">On Oct. 14, Chevron reportedly requested a say in Venture Global, Inc.’s (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/VG\" target=\"_blank\">VG</a>) proposal to delay the startup deadline for its Plaquemines LNG export terminal in Louisiana. This has escalated tensions between the developer and its long-term customers.</p><!--/$--><!--$--><p class=\"block core-block\">Shares of Chevron fell 1% to close at $153.52 on Thursday.</p><!--/$--><!--$--><p class=\"block core-block\">Benzinga readers can access the latest analyst ratings on the <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie\" target=\"_blank\">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p><!--/$--><!--$--><p class=\"block core-block\">Let's have a look at how Benzinga's most-accurate <a href=\"https://www.benzinga.com/quote/GBX/analyst-ratings\" target=\"_blank\">analysts have rated the company</a> in the recent period.</p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li>Raymond James analyst Justin Jenkins reiterated an Outperform rating and cut the price target from $170 to $160 on Oct. 17, 2025. This analyst has an accuracy rate of 78%.</li>\n<li>Wells Fargo analyst Sam Margolin initiated coverage on the stock with an Overweight rating and a price target of $190 on Oct. 17, 2025. This analyst has an accuracy rate of 60%.</li>\n<li>Melius Research analyst James West initiated coverage on the stock with a Hold rating and a price target of $155 on Aug. 20, 2025. This analyst has an accuracy rate of 74%.</li>\n<li>Piper Sandler analyst Ryan Todd maintained an Overweight rating and increased the price target from $164 to $168 on Aug. 18, 2025. This analyst has an accuracy rate of 67%.</li>\n<li>HSBC analyst Kim Fustier downgraded the stock from Buy to Hold and cut the price target from $176 to $158 on May 13, 2025. This analyst has an accuracy rate of 60%</li>\n</ul><!--/$--><!--$--><p class=\"block core-block\">Considering buying CVX stock? Here’s what analysts think: </p><!--/$--><!--$--><!--/$--><!--$--><p class=\"block core-block\"><strong>Read This Next: </strong></p><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><strong><a href=\"https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/10/48524289/jim-cramer-likes-toast-but-isnt-buying-shares-yet\" target=\"_blank\">Jim Cramer Likes Toast, But Isn’t Buying Shares—Yet</a></strong></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\">Photo via Shutterstock</p><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48551407\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/31/West-Linn--Or--Usa---Mar-5--2019-The-Che.jpeg",
            "link": "https://www.benzinga.com/analyst-stock-ratings/price-target/25/10/48551407/top-wall-street-forecasters-revamp-chevron-expectations-ahead-of-q3-earnings",
            "pub_date": "2025-10-31 15:29:46",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "690433b1ecb8a7000145daad",
            "title": "Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?",
            "description": "<div><div class=\"sc-fxwyg khStwV\"><!--$--><p class=\"block core-block\"><strong>MediciNova Inc.</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/MNOV\" target=\"_blank\">MNOV</a>) shares surged 87.39% to $2.23 in after-hours trading on Thursday.</p><!--/$--><!--$--><p class=\"block core-block\"><em>Check out the current price of <a href=\"https://www.benzinga.com/quote/MNOV#Nasdaq\" target=\"_blank\">MNOV stock here</a>. </em></p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Publication Announcement</h2><!--/$--><!--$--><p class=\"block core-block\">The California-based biopharmaceutical company said on Thursday that its research was published in the Journal of Atherosclerosis and Thrombosis, the official publication of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Disease.</p><!--/$--><!--$--><p class=\"block core-block\">The study, \"Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis,\" was carried out in collaboration with a Japanese academic research group.</p><!--/$--><!--$--><div class=\"sc-ewfYpr ctXQJP\"></div><!--/$--><!--$--><h2 class=\"wp-block-heading\">Research Results</h2><!--/$--><!--$--><p class=\"block core-block\">According to the company, the study showed that MN-002, the primary metabolite of the oral bioavailable small molecule MN-001 (tipelukast), increased cholesterol efflux in macrophages by upregulating transport proteins ABCA1 and ABCG1.</p><!--/$--><!--$--><!--/$--><!--$--><div class=\"nativo-placement-in-content-ap\"></div><!--/$--><!--$--><p class=\"block core-block\"><strong>Yuichi Iwaki</strong>, MediciNova president and CEO, said the collaborative research \"provides mechanistic insight into how MN-001 and its metabolite MN-002 may influence cholesterol and lipid metabolism.\"</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Clinical Development</h2><!--/$--><!--$--><p class=\"block core-block\">Prior clinical research demonstrated that MN-001 significantly impacted patients with Type 2 diabetes and improved serum lipid profiles in patients with hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD).</p><!--/$--><!--$--><div class=\"min-w-[300px] w-[300px] min-h-[250px] raptive-ad-placement mx-auto overflow-hidden min-w-[300px]\"></div><!--/$--><!--$--><p class=\"block core-block\">The clinical-stage company is nearing completion of enrollment for a randomized, placebo-controlled, double-blind Phase 2 study in patients with hypertriglyceridemia, type 2 diabetes, and NAFLD.</p><!--/$--><!--$--><h2 class=\"wp-block-heading\">Stock Performance</h2><!--/$--><!--$--><p class=\"block core-block\">MediciNova reported <a href=\"https://www.benzinga.com/quote/MNOV/earnings\" target=\"_blank\">second-quarter earnings</a> on Aug. 14, with a loss of 7 cents per share, beating the 10-cent loss analysts expected. Revenue totaled $134,600, exceeding expectations. </p><!--/$--><!--$--><p class=\"block core-block\">The company is scheduled to report third-quarter results Nov. 12.</p><!--/$--><!--$--><p class=\"block core-block\">MediciNova's 52-week range is $1.13 to $2.55, and its market capitalization stands at $57.87 million.</p><!--/$--><!--$--><p class=\"block core-block\">The stock is down 44.13% year to date.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Price Action: </strong>According to <a href=\"https://www.benzinga.com/quote/MNOV#Nasdaq\" target=\"_blank\">Benzinga Pro</a> data, MediciNova closed Thursday's regular session at $1.19, up 0.85%.</p><!--/$--><!--$--><p class=\"block core-block\"><strong>Benzinga Edge Stock Rankings indicate</strong> that MNOV has a negative price trend across all time frames. <a href=\"https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound\" rel=\"noreferrer noopener\" target=\"_blank\">Track the performance of other players</a> in this segment.</p><!--/$--><!--$--><!--/$--><!--$--><div><div><div class=\"bz-campaign bz-campaign-bottom-48549729\" data-nosnippet=\"true\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div><div class=\"flex sm:hidden flex-col\"><div class=\"sc-c014f608-0 kUPEDz skeleton min-h-[inherit] animate-pulse variant\" role=\"status\"><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div><div class=\"skeleton-child\"></div></div></div></div></div></div><!--/$--><!--$--><!--/$--><!--$--><ul class=\"wp-block-list\">\n<li><a href=\"https://www.benzinga.com/markets/equities/25/10/48549160/amazon-netflix-apple-reddit-and-coinbase-why-these-5-stocks-are-on-investors-radars-today\" target=\"_blank\"><strong>Amazon, Netflix, Apple, Reddit And Coinbase: Why These 5 Stocks Are On Investors’ Radars Today</strong></a></li>\n</ul><!--/$--><!--$--><p class=\"block core-block\"><em>Photo Courtesy: meeboonstudio on Shutterstock.com</em></p><!--/$--><!--$--><p class=\"block core-block\"><strong>Disclaimer:</strong> This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/10/30/A-Businessman-In-A-Suit-Interacts-With-A.jpeg",
            "link": "https://www.benzinga.com/markets/equities/25/10/48549729/why-did-medicinova-stock-mnov-jump-over-87-in-after-hours-trading",
            "pub_date": "2025-10-31 11:57:40",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}